WO1994025027A1 - Btp receptor modulator of the gabaa/chloride channel complex for prolonging the duration of the gaba induced membrane current - Google Patents
Btp receptor modulator of the gabaa/chloride channel complex for prolonging the duration of the gaba induced membrane current Download PDFInfo
- Publication number
- WO1994025027A1 WO1994025027A1 PCT/EP1994/001299 EP9401299W WO9425027A1 WO 1994025027 A1 WO1994025027 A1 WO 1994025027A1 EP 9401299 W EP9401299 W EP 9401299W WO 9425027 A1 WO9425027 A1 WO 9425027A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- gab
- chloride channel
- btp
- die
- duration
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the present invention relates to the therapeutic use of compounds found to 5 modulate a novel allostenc site of the GAB A A /Chloride channel complex.
- Benzodiazepines exhibit a wide range of pharmacological actions, including anxiolytic activity which are mediated by specific high affinity receptor sites in the central nervous system.
- the benzodiazepine receptor is one constituent of a supra molecular complex which also contains separate, but allosterically coupled, recognition sites for 0 ⁇ -aminobutyric acid (GABA) and barbiturates.
- GABA 0 ⁇ -aminobutyric acid
- barbiturates The oligomeric units of the
- GAB A A /Chloride complex form a drug and transmitter controlled chloride channel. In the presence of GABA this channel is opened causing a GAB A-induced chloride ion current.
- GAB A-induced chloride ion current It is known that [35S]-t-butyl-bicyclophosphorothionate (TBPS) binds with high affinity to the GAB A A complex when the chloride channel is in the closed state but with 5 low affinity when in the open state.
- Anxiolytics such as benzodiazepines and barbiturates allosterically inhibit TBPS binding and it is thought that they do this by promoting GAB A induced chloride conductance, Le. shifting the channel to the open state.
- PCT/GB92/02046 and PCT/GB92/02298 disclose certain ⁇ -carboline and tetrahydro- benzothienopyridine derivatives having CNS activity, such as anxiolytic, anti-depressant or anticonvulsant activity or activity useful in the treatment of sleep disorders.
- CNS activity such as anxiolytic, anti-depressant or anticonvulsant activity or activity useful in the treatment of sleep disorders.
- the latter five applications also disclose that such compounds inhibit TBPS binding implying that 5 they modulate the GAB A A /Chloride channel in similar manner to conventional anxiolytics such as the benzodiazepines and barbiturates.
- the present invention provides the use of a BTP receptor modulator of the GAB A A /Chloride channel complex in the manufacture of a medicament for prolonging the duration of the GAB A-induced membrane current
- the present invention provides the use of a BTP receptor modulator of the GAB A A /Chloride channel complex excluding compounds disclosed in the above-noted patent applications in the manufacture of a medicament for the treatment and/or prophylaxis of CNS disorders such as anxiety, sleep disorders, depression or disorders treatable with anti-convulsant agents, such as epilepsy, without the side effects normally associated with the benzodiazepine or barbiturate GAB A A /Chloride channel modulators.
- the present invention provides the use of a compound which prolongs the duration of the GAB A-induced membrane current excluding compounds disclosed in the above-noted patent applications in the manufacture of a medicament for the treatment and/or prophylaxis of CNS disorders such as anxiety, sleep disorders, depression or disorders treatable with anti-convulsant agents, such as epilepsy, without th side effects normally associated with the benzodiazepine or barbiturate GAB A A /Chloride channel modulators.
- BTP receptor modulators of the GAB A A /Chloride channe complex which prolong the duration of the GABA-induced membrane current include :
- a BTP receptor modulator will be administered as a pharmaceutical composition comprising the active medicament, and a pharmaceutically acceptable carrier.
- a pharmaceutical composition of the invention which may be prepared by admixture, suitably at ambient temperature and atmospheric pressure, is usually adapted fo oral or parenteral administration and, as such, may be in the form of tablets, capsules, oral liquid preparations, powders, granules, lozenges, reconstitutable powders, or injectable or infusable solutions or suspensions. Orally administrable compositions are generally preferred.
- Tablets and capsules for oral administration may be in unit dose form, and may contain conventional excipients, such as binding agents, fillers, tabletting lubricants, disintegrants and acceptable wetting agents.
- the tablets may be coated according to methods well known in normal pharmaceutical practice.
- Oral liquid preparations may be in the form of, for example, aqueous or oily suspension, solutions, emulsions, syrups or elixirs, or may be in the form of a dry product for reconstitution with water or other suitable vehicle before use.
- Such liquid preparations may contain conventional additives such as suspending agents, emulsifying agents, non-aqueous vehicles (which may include edible oils), preservatives, and, if desired, conventional flavourings or colourants.
- fluid unit dosage forms are prepared utilising a compound of the invention or pharmaceutically acceptable salt thereof and a sterile vehicle
- the compound depending on the vehicle and concentration used, can be either suspended dissolved in the vehicle.
- the compound can be dissolved for injecti and filter sterilised before filling into a suitable vial or ampoule and sealing.
- adjuvants such as a local anaesthetic, preservatives and buffering agents a dissolved in the vehicle.
- the composition can be frozen after filli into the vial and the water removed under vacuum.
- Parenteral suspensions are prepared in substantially the same manner, except that the compound is suspended in the vehicle instea of being dissolved, and sterilization cannot be accomplished by filtration.
- the compound can be sterilised by exposure to ethylene oxide before suspension in a sterile vehicle.
- a surfactant or wetting agent is included in the composition to facilitate uniform distribution of the compound.
- the composition may contain from 0.1 % to 99% by weight, preferably from 10 to
- suitable unit doses may be 0.05 to 1000 mg, for anxiety more suitably 0.05 to 20.0 mg, for example 0.2 to 10 mg; and such u doses may be administered more than once a day, for example two or three a day, so that t total daily dosage is in the range of about 0.01 to 100 mg/kg; and such therapy may exten for a number of weeks or months.
- the present invention provides a method of screening a compound for use in the treatment and/or prophylaxis of CNS disorders such as anxiety, sleep disorders, depression or disorders treatable with anti-convulsant agents, such as epilepsy, without the side effects normally associated with the benzodiazepine or barbitur GAB A A /Chloride channel modulators which method comprises measuring the ability of a compound to prolong die duration of the GAB A-induced membrane current.
- Bovine adrenomedullary chromaffin cells were isolated and cultured by die method of Peters et al. (1989) and used for electrophysiological recordings 1-2 days after plating.
- cells were continually perfused with a solution containing (mM): NaCl 140, KC12.5, CaCl2 1.5, MgCl2 1.2, HEPES 10 and glucose 10 (pH adjusted to 7.4 with NaOH).
- the perfiision system operates by gravity an uses large bore tubing placed directly in line with the cell. This system allows rapid solution exchange at the cell surface with exchange possible within approximately 100ms.
- the patch pipette solution contained in mM: CsCl 140, MgCl24, HEPES 10, EGTA 10 and NaATP 2, and was adjusted to pH 7.2 with CsOH.
- cells were held at a membrane potential of around -80mV in the 'whole-cell configuration' of the patch clamp technique (Hamill et al. 1981).
- Currents were evoked in response to a pulse of GABA or GABA plus the test compound which is applied through the perfiision system for approximately 7 seconds.
- Current responses were evoked at approximately one minute intervals and were stored on die computer for latter analysis.
- the figure shows currents evoked from a cell in response to GABA (lOpM) alone and in the presence of modulating drugs.
- Compound A, pentobarbitone and diazepam all potentiated die GAB A-induced current with Compound A having the additional effect of dramatically slowing the decay rate of the current on washout of GABA.
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP94915541A EP0697870A1 (en) | 1993-05-05 | 1994-04-26 | Btp receptor modulator of the gaba a?/chloride channel complex for prolonging the duration of the gaba induced membrane current |
JP6523865A JPH08509717A (en) | 1993-05-05 | 1994-04-26 | BTP Receptor Modulators of GABA Under A / Chloride Channel Complex for Prolonging the Duration of GABA-Induced Membrane Currents |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB939309179A GB9309179D0 (en) | 1993-05-05 | 1993-05-05 | New use |
GB9309179.1 | 1993-05-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1994025027A1 true WO1994025027A1 (en) | 1994-11-10 |
Family
ID=10734911
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP1994/001299 WO1994025027A1 (en) | 1993-05-05 | 1994-04-26 | Btp receptor modulator of the gabaa/chloride channel complex for prolonging the duration of the gaba induced membrane current |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP0697870A1 (en) |
JP (1) | JPH08509717A (en) |
GB (1) | GB9309179D0 (en) |
WO (1) | WO1994025027A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6121290A (en) * | 1996-05-24 | 2000-09-19 | Smithkline Beecham Corporation | Use of GABA uptake inhibitors as anti-tussive agents |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0249301A1 (en) * | 1986-01-11 | 1987-12-16 | Beecham Group Plc | Pyrido[2,3-b]indoles |
EP0327223A1 (en) * | 1988-01-22 | 1989-08-09 | Beecham Group Plc | Anxiolytic and antidepressant tetrahydrobenzothienopyridine derivatives |
EP0372962A2 (en) * | 1988-12-09 | 1990-06-13 | Beecham Group Plc | Quinindolinone derivatives, process and intermediates for their preparation and pharmaceutical compositions containing them |
WO1991017165A1 (en) * | 1990-05-08 | 1991-11-14 | Beecham Group Plc | Tetrahydrobenzothienopyridines, processes for their preparation and their use as pharmaceuticals |
WO1993004068A1 (en) * | 1991-08-13 | 1993-03-04 | Smithkline Beecham Plc | Cns active tetrahydrobenzothienopyridines |
WO1993009122A1 (en) * | 1991-11-07 | 1993-05-13 | Smithkline Beecham Plc | Cns active tetrahydrobenzothienopyridines |
WO1993013104A1 (en) * | 1991-12-21 | 1993-07-08 | Smithkline Beecham Plc | C.n.s. active tricyclic thienopyridine derivatives |
-
1993
- 1993-05-05 GB GB939309179A patent/GB9309179D0/en active Pending
-
1994
- 1994-04-26 JP JP6523865A patent/JPH08509717A/en active Pending
- 1994-04-26 WO PCT/EP1994/001299 patent/WO1994025027A1/en not_active Application Discontinuation
- 1994-04-26 EP EP94915541A patent/EP0697870A1/en not_active Withdrawn
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0249301A1 (en) * | 1986-01-11 | 1987-12-16 | Beecham Group Plc | Pyrido[2,3-b]indoles |
EP0327223A1 (en) * | 1988-01-22 | 1989-08-09 | Beecham Group Plc | Anxiolytic and antidepressant tetrahydrobenzothienopyridine derivatives |
EP0372962A2 (en) * | 1988-12-09 | 1990-06-13 | Beecham Group Plc | Quinindolinone derivatives, process and intermediates for their preparation and pharmaceutical compositions containing them |
WO1991017165A1 (en) * | 1990-05-08 | 1991-11-14 | Beecham Group Plc | Tetrahydrobenzothienopyridines, processes for their preparation and their use as pharmaceuticals |
WO1993004068A1 (en) * | 1991-08-13 | 1993-03-04 | Smithkline Beecham Plc | Cns active tetrahydrobenzothienopyridines |
WO1993009122A1 (en) * | 1991-11-07 | 1993-05-13 | Smithkline Beecham Plc | Cns active tetrahydrobenzothienopyridines |
WO1993013104A1 (en) * | 1991-12-21 | 1993-07-08 | Smithkline Beecham Plc | C.n.s. active tricyclic thienopyridine derivatives |
Non-Patent Citations (2)
Title |
---|
E. BROUILLET ET AL.: "In vivo bidirectional modulatory effect of benzodiazepine receptor ligands on GABAergic transmission evaluated by positron emisson tomography in non-human primates", BRAIN RES., vol. 557, no. 1-2, 1991, pages 167 - 176 * |
S. DEUTSCH ET AL.: "GABA-active Steroids: Endogenous modulators of GABA-gated chloride ion conductance", CLIN. NEUROPHARMACOL., vol. 15, no. 5, 1992, pages 352 - 364 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6121290A (en) * | 1996-05-24 | 2000-09-19 | Smithkline Beecham Corporation | Use of GABA uptake inhibitors as anti-tussive agents |
Also Published As
Publication number | Publication date |
---|---|
JPH08509717A (en) | 1996-10-15 |
EP0697870A1 (en) | 1996-02-28 |
GB9309179D0 (en) | 1993-06-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Freedman et al. | Identification and characterization of voltage-sensitive calcium channels in neuronal clonal cell lines | |
RU2225203C2 (en) | Pharmaceutical composition comprising positive modulator of nicotine receptor agonist and agonist of nicotine receptor, method for treatment | |
Delpy et al. | NKCC1 cotransporter inactivation underlies embryonic development of chloride‐mediated inhibition in mouse spinal motoneuron | |
Bevan et al. | Capsazepine: a competitive antagonist of the sensory neurone excitant capsaicin | |
Konradi et al. | Antipsychotic drugs and neuroplasticity: insights into the treatment and neurobiology of schizophrenia | |
JP5390184B2 (en) | Improved treatment of anemia | |
DE60214846T2 (en) | Use of mGLuR5 antagonists for the manufacture of medicaments for the treatment of sensitive X syndromes, autism and mental retardation | |
US20040092528A1 (en) | Agent for modulating excitatory synaptic transmission comprising a compound having alpha7 nicotinic acetylcholine receptor activation property | |
Ling et al. | Cyclosporin A inhibits apical secretory K+ channels in rabbit cortical collecting tubule principal cells | |
AU672334B2 (en) | Treatment of anxiety with the aid of (S)-(-)-alpha-ethyl-2- oxo-1-pyrrolidineacetamide | |
Green et al. | Should clozapine be a first-line treatment for schizophrenia? The rationale for a double-blind clinical trial in first-episode patients | |
Gregory et al. | Evidence that Ca2+-release-activated Ca2+ channels in rat hepatocytes are required for the maintenance of hormone-induced Ca2+ oscillations | |
Smitherman et al. | Inhibition of glial Na+ and K+ currents by tamoxifen | |
WO1994025027A1 (en) | Btp receptor modulator of the gabaa/chloride channel complex for prolonging the duration of the gaba induced membrane current | |
EP1658062B1 (en) | Alpha-aminoamide derivatives useful as anti-inflammatory agents | |
DE69910425T2 (en) | NEW THERAPEUTIC USE OF NICERGOLINE | |
Brown et al. | Block of human voltage‐sensitive Na+ currents in differentiated SH‐SY5Y cells by lifarizine | |
UA51682C2 (en) | Flupitrin as active substance for preventing and treating diseases involving induced apoptosis of lymphocytes | |
DE69319346T2 (en) | TREATMENT OF TUMORS WITH NEUTROPHIC FACTORS AND INHIBITORS OF CELL PROLIFERATION | |
CN103202845B (en) | Pharmaceutical Composition Of A Sodium Channel Blocker And A Selective Serotonin Uptake Inhibitor | |
US6350768B1 (en) | Combination of riluzole and of gabapentin and its use as a medicament | |
White et al. | 1, 9-Dideoxyforskolin does not mimick all cAMP and protein kinase a independent effects of forskolin on GABA activated ion currents in adult rat sensory neurons | |
Leslie | Calcium channels: interactions with ethanol and other sedative-hypnotic drugs | |
Ito et al. | Haloperidol effects on Na current in acutely isolated rat retinal ganglion cells | |
AU772516B2 (en) | Antitumor agents |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1994915541 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref country code: US Ref document number: 1996 545662 Date of ref document: 19960130 Kind code of ref document: A Format of ref document f/p: F |
|
WWP | Wipo information: published in national office |
Ref document number: 1994915541 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1994915541 Country of ref document: EP |